Werewolf Therapeutics, Inc.
US ˙ NasdaqGS ˙ US95075A1079

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mpm Asset Management Llc. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mpm Asset Management Llc has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:HOWL / Werewolf Therapeutics, Inc. 10% Owner 6,718,670
US:TCRR / Tcr2 Therapeutics Inc 10% Owner 0
US:HARP / Harpoon Therapeutics, Inc. 3,220,844
US:ONCR / Oncorus, Inc. 10% Owner 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mpm Asset Management Llc. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases HOWL / Werewolf Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in HOWL / Werewolf Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HOWL / Werewolf Therapeutics, Inc. Insider Trades
Insider Sales HOWL / Werewolf Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in HOWL / Werewolf Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-03-27 HOWL GADICKE ANSBERT 4,386 1.0500 4,386 1.0500 4,605 11 0.6300 -1,842 -40.00

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

HOWL / Werewolf Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mpm Asset Management Llc as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-04-30 2025-03-27 4 HOWL Werewolf Therapeutics, Inc.
Common Stock
S - Sale -4,386 6,718,670 -0.07 1.05 -4,605 7,054,604
2025-04-30 2025-03-27 4 HOWL Werewolf Therapeutics, Inc.
Common Stock
X - Other 50,873 6,723,056 0.76 0.09 4,579 605,075
2023-06-05 2023-06-01 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
J - Other -4,158,964 0 -100.00
2023-05-24 2023-05-22 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
S - Sale -70,170 304,001 -18.75 1.88 -131,920 571,522
2023-05-24 2023-05-22 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
X - Other 178,269 374,171 91.00 0.74 131,919 276,887
2021-04-15 2021-04-15 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -1,052 3,220,844 -0.03 20.49 -21,555 65,995,094
2021-04-15 2021-04-14 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -1,550 3,221,896 -0.05 20.83 -32,286 67,112,094
2021-04-15 2021-04-14 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -121 3,223,446 0.00 20.06 -2,427 64,662,327
2021-04-15 2021-04-13 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -286 3,223,567 -0.01 20.08 -5,743 64,729,225
2021-04-15 2021-04-13 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -1,657 3,223,853 -0.05 19.35 -32,063 62,381,556
2021-04-13 2021-04-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -48 3,225,510 0.00 22.68 -1,089 73,154,567
2021-04-13 2021-04-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -811 3,225,558 -0.03 21.52 -17,453 69,414,008
2021-04-13 2021-04-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -1,637 3,226,369 -0.05 20.72 -33,919 66,850,366
2021-04-13 2021-04-09 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -10,300 3,228,006 -0.32 23.67 -243,801 76,406,902
2021-02-12 2021-02-10 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -183,051 3,238,306 -5.35 20.00 -3,661,020 64,766,120
2021-02-09 2021-02-09 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -9,400 3,421,357 -0.27 20.25 -190,350 69,282,479
2021-02-09 2021-02-08 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -72,128 3,430,757 -2.06 20.04 -1,445,445 68,752,370
2021-02-09 2021-02-05 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -10,172 3,502,885 -0.29 20.01 -203,542 70,092,729
2021-02-04 2021-02-04 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -29,730 3,513,057 -0.84 20.37 -605,600 71,560,971
2021-02-04 2021-02-03 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -41,922 3,542,787 -1.17 20.21 -847,244 71,599,725
2021-02-04 2021-02-02 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -48,421 3,584,709 -1.33 20.13 -974,715 72,160,192
2021-01-27 2021-01-27 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -706,825 3,633,130 -16.29 20.00 -14,136,500 72,662,600
2021-01-27 2021-01-26 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -1,363 4,339,955 -0.03 21.08 -28,732 91,486,251
2021-01-27 2021-01-25 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -13,006 4,341,318 -0.30 21.23 -276,117 92,166,181
2021-01-22 2021-01-22 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -24,695 4,354,324 -0.56 21.72 -536,375 94,575,917
2021-01-22 2021-01-21 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -200 4,379,019 0.00 23.77 -4,754 104,089,282
2021-01-22 2021-01-21 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -4,887 4,379,219 -0.11 22.61 -110,495 99,014,142
2021-01-22 2021-01-21 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -20,979 4,384,106 -0.48 22.11 -463,846 96,932,584
2021-01-22 2021-01-20 4 HARP Harpoon Therapeutics, Inc.
Common Stock
J - Other X -101,646 4,405,085 -2.26
2021-01-22 2021-01-20 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -2,000 4,506,731 -0.04 24.71 -49,420 111,361,323
2021-01-22 2021-01-20 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale X -15,694 4,508,731 -0.35 23.95 -375,871 107,984,107
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Series B Preferred Stock
C - Conversion -775,975 0 -100.00
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Series A-1 Preferred Stock
C - Conversion -1,783,879 0 -100.00
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Common Stock
P - Purchase 173,776 2,849,453 6.49 15.00 2,606,640 42,741,795
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Common Stock
C - Conversion 775,975 2,675,677 40.85
2020-10-08 2020-10-06 4 ONCR Oncorus, Inc.
Common Stock
C - Conversion 1,783,879 1,899,702 1,540.18
2020-10-01 3 ONCR Oncorus, Inc.
Common Stock
115,823
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series B Preferred Stock
C - Conversion -2,000,000 0 -100.00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Series A Preferred Stock
C - Conversion -17,500,000 0 -100.00
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
P - Purchase 706,666 4,050,865 21.13 15.00 10,599,990 60,762,975
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 322,901 3,344,199 10.69
2019-02-21 2019-02-19 4 TCRR TCR2 THERAPEUTICS INC.
Common Stock
C - Conversion 2,825,396 3,021,298 1,442.25
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -50,837 0 -100.00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -50,837 0 -100.00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -76,256 0 -100.00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -171,579 0 -100.00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -57,192 0 -100.00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock Warrant (Right to Buy)
X - Other -25,418 0 -100.00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Series C Preferred Stock
C - Conversion -417,852 0 -100.00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Series B Preferred Stock
C - Conversion -1,578,751 0 -100.00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Series A Preferred Stock
C - Conversion -1,525,164 0 -100.00
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
P - Purchase 250,000 4,524,425 5.85 14.00 3,500,000 63,341,950
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
S - Sale -1,524 4,274,425 -0.04 14.00 -21,336 59,841,950
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
X - Other 432,119 4,275,949 11.24 0.05 21,260 210,377
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
C - Conversion 417,852 3,843,830 12.20
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
C - Conversion 1,578,751 3,425,978 85.47
2019-02-14 2019-02-12 4 HARP Harpoon Therapeutics, Inc.
Common Stock
C - Conversion 1,525,164 1,847,227 473.56
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391,804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391,804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391,804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391,804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391,804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391,804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391,804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391,804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391,804
2019-02-13 3 TCRR TCR2 THERAPEUTICS INC.
Common Stock
391,804
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644,126
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644,126
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644,126
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644,126
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644,126
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644,126
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644,126
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644,126
2019-02-07 3 HARP Harpoon Therapeutics, Inc.
Common Stock
644,126
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)